Han Chong Toh:international phase 2 trial of linifanib(ABT-869)in patients with advanced hepatocellular carcinoma(HCC):Analysis by Chinese and non-Chinese ethnicity
international phase 2 trial of linifanib(ABT-869)in patients with advanced hepatocellular carcinoma(HCC):Analysis by Chinese and non-Chinese ethnicity
Han Chong Toh:National Cancer Center,Singapore
Han Chong Toh主题报告
Han Chong Toh主题报告
Han Chong Toh主题报告
Han Chong Toh主题报告
Han Chong Toh主题报告
Han Chong Toh主题报告
编辑: yishuitan
以下网友留言只代表网友个人观点,不代表网站观点
